AI brief of an SEC Form 8-K · Axogen, Inc. (AXGN)

Axogen Completes BioCircuit Acquisition, Adding NerveTape Sutureless Nerve Repair Device

Positive Impact 3 of 5 m&a Written later

Axogen, Inc. (Nasdaq: AXGN) said on October 1, 2026 that it completed its previously announced acquisition of privately held BioCircuit Technologies, Inc., maker of the NerveTape sutureless nerve repair device. The company expects BioCircuit to add about $6 million to fourth-quarter 2026 revenue and about $34 million to 2027 revenue, a contribution not included in its full-year 2026 guidance of at least 24% revenue growth. The filing does not disclose the purchase price.

Key points

Acquisition of BioCircuit Technologies, Inc. completed; announced October 1, 2026
Expected BioCircuit revenue contribution: about $6 million in Q4 2026 and about $34 million in 2027
Contribution is not included in the existing full-year 2026 guidance of at least 24% revenue growth
Company continues to expect gross margin of at least 73% and positive free cash flow for full-year 2026

The filing

CompanyAxogen, Inc. (AXGN)

Form8-K, current report

Filed with the SECOct 1, 2026, 5:25 PM ET

Accession number0000805928-26-000104

Items reported: 7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:51 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 01, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.